Aktis Oncology Clears FDA Hurdle for AKY-2519, Sets Mid-2026 Trial Start
Event summary
- FDA cleared IND applications for AKY-2519, enabling Phase 1b trial initiation mid-2026.
- AKY-1189 Phase 1b trial ongoing with Fast Track designation for urothelial cancer.
- 2025 revenue: $6.5M (up from $1.5M in 2024) driven by Eli Lilly collaboration.
- Pro forma cash position: $562.1M post-$365.4M January 2026 IPO.
- GMP facility expected operational in second half of 2026.
The big picture
Aktis Oncology is advancing its proprietary miniprotein radioconjugate platform to target broader solid tumor populations, competing with existing radiopharmaceutical technologies. The FDA clearances for AKY-2519 and Fast Track designation for AKY-1189 position the company to capture market share in high-unmet-need indications. The $365.4M IPO provides substantial capital to accelerate clinical development and manufacturing capabilities.
What we're watching
- Clinical Momentum
- Whether Aktis can deliver preliminary AKY-1189 data by Q1 2027 and initiate AKY-2519 Phase 1b trial mid-2026 as planned.
- Financial Runway
- How the $562.1M pro forma cash position will support operations through 2029 amid rising R&D expenses.
- Pipeline Expansion
- The pace at which early pipeline programs advance toward development candidate nomination by Q1 2027.
Related topics